Conformational flexibility of the pharmacologically important insulin analogues

Abstract

Understanding the conformational flexibility of the insulin drugs is of great importance for the treatment of diabetes mellitus. Once in the body, the drug must have a certain degree of mobility within a specified period of time for the manifestation of its pharmacological properties. This mobility ensures conformational states necessary for binding with the insulin receptor and activating specific biological processes. In this work we investigated conformational flexibility of the pharmacologically important insulin analogues—insulin lispro, insulin aspart, insulin glulisine, and insulin glargine, using the molecular dynamics simulation method. This study provides new insight into the nature of behaviour of A-and B-chains. It has been found out that B-chain substitutions result in rapid acting, while long-lasting action can be achieved by substitutions in both chains. The results of this study can be used for development of new insulin-based antidiabetic drugs.

Share and Cite:

Ksenofontova, O. and Stefanov, V. (2013) Conformational flexibility of the pharmacologically important insulin analogues. Advances in Biological Chemistry, 3, 512-517. doi: 10.4236/abc.2013.35056.

1. INTRODUCTION

Vitamin D deficiency is not only associated with osteoporosis and osteomalacia [1,2] but can also contribute to decreased muscle strength [3], cancers [4], cardiovascular disease [5], type 1 diabetes mellitus [6] and overall mortality [7]. These findings have increased the need for determining vitamin D status in a reliable way. There are many commercially available 25-hydroxyvitamin D (25OHD) assays used for determination of vitamin D status. These include high-pressure liquid chromatography (HPLC) [8], enzyme immunoassays (EIA), and chemiluminescent immunoassays (CLIA). Determination of 25OHD by HPLC can be considered the gold standard method [9]. However, it is accepted that these methods are unsuitable for routine, clinical laboratory use as the method is very time consuming, requiring extensive purification steps [10]. But there is still continuing uncertainty as which method should be adopted to measure the concentration of vitamin D or should be estimated easily to be the definite way. So, the present study therefore is to investigate which method is cost-effective and reliable to analyse the vitamin D status.

2. MATERIAL AND METHOD

2.1. Study Area

The present study was conducted in the Department of Biochemistry of Burdwan Medical College, Burdwan in collaboration of Department of Biochemistry, Medical College, Kolkata and Gautam Laboratories, Kolkata, West Bengal.

2.2. Selection of Subjects

One thousand patients residing Burdwan district and adjoining areas were selected in this study. Patients having any concomitant infection and recent history of taking drugs that can affect the blood vitamin D concentration were not included in the study. Then two hundred and sixteen subjects were selected by a simple random method for this study. All the patients were accepted to participate by giving informed consent. The proposal of this study was approved by the Ethics Committee of Burdwan Medical College, West Bengal.

2.3. Collection of Samples

After noting the age and sex, venous blood samples were collected after a 12-h overnight fasting, protected from light, centrifuged and stored at −80˚C until analysis.

2.4. Parameter Assay

Vitamin D in all samples was analyzed using three techniques HPLC, CLIA and EIA.

2.4.1. High-Pressure Liquid Chromatography (HPLC)

Determination of 25-hydroxyvitamin D in plasma was done by HPLC (JASCO open HPLC system; Model: LC NET II/ADC, Detector: UV-2075plus, pump LC-2080 series, Software: SF-NAV with DG-2080-53/4) using a C18 reverse phase column with gradient elution (acetonitrile/water). The HPLC unit was an integrated system with a UV-2075plus detector set at 275 nm. The coefficients of Variation (CV) for inter-assay analyses are 5.1% at 25-hydroxyvitamin D of 47.8 nmol/L and 6.9% at 25-hydroxyvitamin D of 83.0 nM. [8]

To prepare samples, 2 ml of precipitation reagent with internal standard was dispensed into a disposable glass test tube. Then 1.0 ml of serum (calibrator, control, or patient sample) was added to the tube without mixing of contents to avoid balling of the protein. The tube was allowed to sit for 5 min at room temperature, after which it was mixed in a vortex for 10 seconds to obtain a flocculent precipitate. After waiting for another 5 min the tube was again vortex-mixed and centrifuged at 2000 g for 10 min. The clear supernatant was decanted into a disposable glass test tube which was protected from exposure to natural sunlight to prevent degradation of analytes. The unit sequentially was conditioned the Strata-X cartridge in the DEC zone with 2.0 ml of CH3CN followed by 2.0 ml of 35:65 CH3CN-water. Then 1.0 ml of water was added to each extract and transferred 3.5 ml of extract mixture to the DEC. Then the DEC was rinsed with 2.0 ml of 35:65 CH3CN–water and was eluted the Strata-X cartridge in the DEC zone with 2.0 ml of CH3CN. The eluate was dried at 35˚C under a stream of nitrogen and the dry extract was then reconstituted with 150 µl of ethyl acetate-CH3CN (5:95 by volume) and vortex-mixed for 5 seconds. Water (110 µL) was then added to the tube, and the contents were vortex mixed for 5 seconds. The sample was centrifuged at 2000 g for 10 min to settle the precipitate. The clear liquid was transferred to an amber coloured vial. The sample was finally capped. The extract was stable for 3 days at room temperature. The processor software calculated relative retention time for peak identification and peak-height ratio for quantification.

2.4.2. Chemiluminiscent Immunoassay (CLIA)

25-hydroxyvitamin D in serum was measured with automated chemiluminiscent immunoassay technology (VITROS eci, Johnson and Johnson Ortho Clinical Diagnostics). CV for inter-assay analyses is 5.8% at a 25- hydroxyvitamin D level of 39.5 nmol/L and 3.1% at 121.25 nmol/L [11].

2.4.3. EIA

Vitamin D of the subjects was also estimated using solid phase Enzyme Linked Immunosorbent Assay performed (EIA) on microtiterplates (DIAsource ImmunoAssays, Belgium). Within-run CV including extraction 6.8%, and between-run CV 6.2% [10].

2.5. Statistical Analysis

The data for biochemical analysis was subjected to standard statistical analysis using the Statistical Package for Social Science (SPSS) 11.5 software for windows.

3. RESULT

The personal profiles and clinical parameters of all the subjects under study are shown in Table 1.

Mean value of blood vitamin D obtained by HPLC method (69.34 nmole/L) are more close to CLIA (68.46 nmole/L) than EIA (67.18 nmole/L). Another observation is that concentration vitamin D in EIA has lower mean has wider SD and confidence interval than other two samples as shown in Table 2.

Table 1. Personal profiles of the subjects.

Value are mean ± SD; n = number of cases.

Table 2. Comparison of mean value of three methods of blood vitamin D estimation.

Values are mean ± SD; CI = confidence interval.

Regression analysis is performed to evaluate which method of vitamin D estimation and which method shows best correlate with HPLC. Over the whole range of vitamin D values in HPLC, the CLIA shows a higher r value (r = 0.978, p < 0.0001) and EIA a lower r value (r = 0.970, p < 0.0001) of vitamin D of same individual. That signifies that values of vitamin D in CLIA of the subjects is more significantly correlated with value obtained from HPLC than EIA as shown in Table 3 and Figure 1.

The area under the curve (AUC) of ROC curve be-

Table 3. Pearson correlation of HPLC with CLIA and EIA.

(a)(b)

Figure 1. Scatter diagram (a) Correlation of vitamin D concentration between HPLC & CLIA method (b) Correlation of vitamin D between HPLC & EIA method.

tween values of blood vitamin D obtained by HPLC and CLIA is more than between HPLC and EIA as shown in Table 4 and Figure 2.

4. DISCUSSION

Deficiency of vitamin D is common and represents a major health problem. Early in life, vitamin D deficiency causes growth retardation and rickets, whereas in adults it is well known to accelerate osteopenia and osteoporosis. Accumulating evidence also links a low vitamin D nutritional status to highly prevalent chronic illnesses, including common cancers, autoimmune diseases, infectious and cardiovascular diseases [12-14]. Rapid screening for vitamin D status is essential as it allows for monitoring a patient’s response to vitamin D therapy and

Table 4. Area under the ROC curve and CI between the different methods of serum vitamin D estimation.

(a)(b)

Figure 2. Receiver Operative Characteristic (ROC) curves of methods of serum vitamin D (a) HPLC and CLIA (b) HPLC and EIA.

also evaluation of treatment effect [10] therefore, samples providing immediate and reliable results are highly desirable. Clinical laboratory scientists have a diverse array of vitamin D testing methods from which to choose. With the respect to vitamin D estimation chromatographic separation is suitable as a reference method 15, since it is capable of resolving D2 and D3 forms as well as the 25OH, 1,25(OH)2 and 24,25(OH)2 metabolites. A C18 reverse phase column with isocratic or gradient elution using acetonitrile/water is now the standard procedure and diode array detection following hexane extraction gives results of sufficient clinical sensitivity [15]. Whilst the reference method is suitable for vitamin D estimation, their complexity and derivatisation requirements mitigate against regular use. More practical and easier alternatives method is CLIA or EIA [16]. The introduction of antibody preparations against vitamin D metabolites made it possible to develop assays that generally are more specific vitamin D assays, thus requiring fewer purification steps and thus reduces time (1). In present study, when cut-off values are used that are advocated in reagent manual, the value of vitamin D of CLIA are more closed to the HPLC than value obtained by EIA. So, CLIA can replace the HPLC method which is too much lengthy. Previous study also gives support towards this factor due to easy performance, low cost and high sensitivity (1).

5. CONCLUSION

The study concluded that CLIA not the EIA could replace the HPLC for estimation of blood vitamin D effectively and can be used as a rapid screening test for vitamin D status and for monitoring a patient’s response to vitamin D therapy for reasons of convenience, speed, turnaround time and cost.

6. ACKNOWLEDGEMENTS

Authors are thankful to Mr.Kamal Kumar Mukim, Director, Gautam Laboratories, Kolkata and Mr. Pinaki Karmakar, Technician, Department of Immunohematology, Gautam Laboratories, Kolkata for constant support & inspiration.

NOTES

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Whiting, D.R., Guariguata, L., Weil, C. and Shaw, J. (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice, 94, 311-321.
http://dx.doi.org/10.1016/j.diabres.2011.10.029
[2] Eisenbarth, G.S. (1986) Type I diabetes mellitus. A chronic autoimmune disease. The New England Journal of Medicine, 314, 1360-1368.
http://dx.doi.org/10.1056/NEJM198605223142106
[3] Hua, Q., Hu, S., Jia, W., Wang, S. and Weiss, M.A. (2005) Toward the Active Conformation of Insulin. Stereospecific modulation of a structural switch in the B chain. The Journal of Biological Chemistry, 281, 24900-24909.
http://dx.doi.org/10.1074/jbc.M602691200
[4] Olsen, H.B., Ludvigsen, S. and Kaarsholm, N.C. (1996) Solution structure of an engineered insulin monomer at neutral pH. Biochemistry, 35, 8836-8845.
http://dx.doi.org/10.1021/bi960292+
[5] Kurtzhals, P. (2004) Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir. International Journal of Obesity, 28, 23-28.
http://dx.doi.org/10.1038/sj.ijo.0802746
[6] Bolli, G.B., Marchi, R.D. Di, Park, G.D., Pramming, S. and Koivisto, V.A. (1999) Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia, 42, 1151-1167.
http://dx.doi.org/10.1007/s001250051286
[7] Hermansen, K., et al. (2004) Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basalbolus therapy for patients with type 1 diabetes. Diabetologia, 47, 622-629.
http://dx.doi.org/10.1007/s00125-004-1365-z
[8] Senesh, G., Bushi, D., Neta,A. and O. Yodfat (2010) Compatibility of insulin lispro, aspart, and glulisine with the SoloTMMicroPump, a novel miniature insulin pump. Journal of Diabetes Science and Technology, 4, 104-110.
[9] Swinnen, S.G.H.A., et al. (2009) Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) treat-to-target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technology and Therapeutics, 11, 739-743.
http://dx.doi.org/10.1089/dia.2009.0044
[10] Chao, M., et al. (2010) Bioequivalence between two human insulin analogs in chinese population: Glulisine and lispro. Endocrine, 38, 48-52.
http://dx.doi.org/10.1007/s12020-010-9326-4
[11] Setter, S.M., Corbett, C.F., Campbell, R.K. and White, J.R. (2000) Insulin aspart: A new rapid-acting insulin analog. The Annals of Pharmacotherapy, 34, 1423-1431.
[12] Garg, S.K., Ellis, S.L. and Ulrich, H. (2005) Insulin glulisine: A new rapid-acting insulin analogue for the treatment of diabetes. Expert Opinion on Pharmacotherapy, 6, 643-651.
http://dx.doi.org/10.1517/14656566.6.4.643
[13] Bolli, G.B. and Owens, D.R. (2000) Insulin glargine. The Lancet, 356, 443-445.
http://dx.doi.org/10.1016/S0140-6736(00)02546-0
[14] Hansen, B.F., et al. (1996) Susteined signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochemical Journal, 315, 271-279.
[15] Hirsch, I.B. (2005) Drug Therapy Insulin Analogues. The New England Journal of Medicine, 352, 174-183.
http://dx.doi.org/10.1056/NEJMra040832
[16] Karplus, M. and Petsko, G.A. (1990) Molecular dynamics simulations in biology. Nature, 347, 631-639.
http://dx.doi.org/10.1038/347631a0
[17] Karplus, M. and McCammon, A. (2002) Molecular dynamics simulations of biomolecules. Nature Structural Biology, 9, 646-652.
http://dx.doi.org/10.1038/nsb0902-646
[18] Budi, A., Legge, S., Treutlein, H. and Yarovsky, I. (2004) Effect of external stresses on protein conformation: A computer modelling study. European Biophysics Journal, 33, 121-129.
http://dx.doi.org/10.1007/s00249-003-0359-y
[19] Legge, F.S., Budi, A., Treutlein, H. and Yarovsky, I. (2006) Protein flexibility: Multiple molecular dynamics simulations of insulin chain B. Biophysical Chemistry, 119, 146-157.
http://dx.doi.org/10.1016/j.bpc.2005.08.002
[20] Zoete, V., Meuwly, M. and Karplus, M. (2005) Study of the insulin dimerization: Binding free energy calculations and per-residue free energy decomposition. Proteins: Structure, Function, and Bioinformatics, 61, 79-93.
http://dx.doi.org/10.1002/prot.20528
[21] Mark, A.E., Berendsen, H.J.C. and Gunsteren, W.F.V. (1991) Conformational flexibility of aqueous monomeric and dimeric insulin: a molecular dynamics study. Biochemistry, 30, 10866-10872.
http://dx.doi.org/10.1021/bi00109a009
[22] Pronk, S., et al. (2013) GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics, 29, 845-854.
http://dx.doi.org/10.1093/bioinformatics/btt055
[23] Eswar, N., Eramian, D., Webb, B., Shen, M. and Sali, A. (2008) Protein structure modeling with MODELLER. Structural Proteomics. Methods in Molecular Biology, 426, 145-159.
http://dx.doi.org/10.1007/978-1-60327-058-8_8
[24] Kaminski, G.A. and Friesner, R.A. (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. The Journal of Physical Chemistry B, 105, 6474-6487.
http://dx.doi.org/10.1021/jp003919d
[25] Humphrey, W., Dalke, A. and Schulten, K. (1996) VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14, 33-38.
http://dx.doi.org/10.1016/0263-7855(96)00018-5
[26] Heller, S., Kozlovski, P. and Kurtzhals, P. (2007) Insulin’s 85th anniversary—An enduring medical miracle. Diabetes Research and Clinical Practice, 78, 149-158.
http://dx.doi.org/10.1016/j.diabres.2007.04.001
[27] Hua, Q. and Weiss, M.A. (2004) Mechanism of insulin fibrillation. The structure of insulin under amyloidogenic conditions resembles a protein-folding. The Journal of Biological Chemistry, 279, 21449-21460.
http://dx.doi.org/10.1074/jbc.M314141200

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.